Compare Gilead Sciences, Inc. (GILD) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs First Trust Cloud Computing ETF — how do they compare? Gilead Sciences, Inc. trades at $134.8 (market cap $163.51B), while First Trust Cloud Computing ETF trades at $137.06. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while First Trust Cloud Computing ETF pays none. Which is the better fit depends on your goals.
| GILD | SKYY | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | — |
52-Week High | $155.80 | $155.17 |
52-Week Low | $108.22 | $104.16 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
First Trust Cloud Computing ETF (SKYY) trades at $137.24, down 1.49% today, with a bullish technical signal driven by moving averages. The ETF provides diversified exposure to the cloud computing sector, which is benefiting from enterprise digital transformation and AI adoption. Recent news highlights continued investor interest in technology ETFs, with SKYY being a prominent option for broad market access.
Outlook remains positive due to structural growth in cloud services, though risks include sector volatility and competitive pressures. Analyst sentiment is generally favorable, emphasizing long-term growth potential from AI and hybrid cloud trends. Investors should weigh sector momentum against valuation concerns in a high-interest-rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
